Clinical Trial Data Transparency on Trial – EMA Under Pressure From Pharma Lawsuit

Thursday 1 December 2016 | Clinical Trial Data | |  Updated 22 December 2016

By Ancel.la Santos, Policy Advisor, Health Action International

For too long, pharmaceutical companies have endangered patient safety by providing biased information about a medicine’s effect on their users.

Tamiflu review shows desperate need for full clinical trials data transparency

by ANCEL.LA SANTOS QUINTANO

Today, the British Medical Journal published the Cochrane Collaboration’s updated systematic review on Tamiflu (oseltamivir).

The inclusion in the review of clinical study reports (CSRs)—comprehensive documents prepared by the pharmaceutical industry for regulatory processes—has been crucial to uncovering the true effects of the drug.

START TYPING AND PRESS ENTER TO SEARCH